

Gui-Qi Zhu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/42922/publications.pdf>

Version: 2024-02-01

61
papers

1,337
citations

361045

20
h-index

414034

32
g-index

61
all docs

61
docs citations

61
times ranked

2293
citing authors

#	ARTICLE	IF	CITATIONS
1	Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 624-635.	1.9	75
2	The miR-561-5p/CXCR3/CL1 Signaling Axis Regulates Pulmonary Metastasis in Hepatocellular Carcinoma Involving CXCR3/CR1 Natural Killer Cells Infiltration. <i>Theranostics</i> , 2019, 9, 4779-4794.	4.6	72
3	Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 21753-21762.	0.8	68
4	Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2016, 6, 33743.	1.6	61
5	Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation. <i>Oncotarget</i> , 2016, 7, 30642-30658.	0.8	57
6	Preoperative platelet to lymphocyte ratio is a valuable prognostic biomarker in patients with colorectal cancer. <i>Oncotarget</i> , 2016, 7, 25516-25527.	0.8	52
7	Association Between Sex-Specific Serum Uric Acid and Non-Alcoholic Fatty Liver Disease in Chinese Adults. <i>Medicine (United States)</i> , 2015, 94, e802.	0.4	50
8	Metabolic syndrome contributes to an increased recurrence risk of non-metastatic colorectal cancer. <i>Oncotarget</i> , 2015, 6, 19880-19890.	0.8	43
9	Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 171.	3.5	42
10	Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis. <i>Oncotarget</i> , 2015, 6, 18151-18161.	0.8	39
11	Increased levels of low-density lipoprotein cholesterol within the normal range as a risk factor for nonalcoholic fatty liver disease. <i>Oncotarget</i> , 2016, 7, 5728-5737.	0.8	37
12	Prognostic alternative mRNA splicing signature in hepatocellular carcinoma: a study based on large-scale sequencing data. <i>Carcinogenesis</i> , 2019, 40, 1077-1085.	1.3	34
13	Increased Levels of Systolic Blood Pressure Within the Normal Range Are Associated With Significantly Elevated Risks of Nonalcoholic Fatty Liver Disease. <i>Medicine (United States)</i> , 2015, 94, e842.	0.4	32
14	Identification and validation of tumour microenvironment-based immune molecular subgroups for gastric cancer: immunotherapeutic implications. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1057-1069.	2.0	31
15	Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 759-770.	1.9	28
16	Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 675-685.	1.5	28
17	HNRNPAB-regulated lncRNA ELF209 inhibits the malignancy of hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2020, 146, 169-180.	2.3	28
18	Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. <i>Medicine (United States)</i> , 2015, 94, e802.	0.4	23

#	ARTICLE	IF	CITATIONS
19	Platelet-to-Lymphocyte Ratio. <i>Medicine (United States)</i> , 2016, 95, e2596.	0.4	23
20	Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 375-387.	1.5	22
21	Splicing factors: Insights into their regulatory network in alternative splicing in cancer. <i>Cancer Letters</i> , 2021, 501, 83-104.	3.2	22
22	A network meta-analysis of the efficacy and side effects of udca-based therapies for primary sclerosing cholangitis. <i>Oncotarget</i> , 2015, 6, 26757-26769.	0.8	22
23	Nonalcoholic Fatty Liver Disease. <i>Medicine (United States)</i> , 2015, 94, e479.	0.4	21
24	Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study. <i>Molecular Oncology</i> , 2022, 16, 549-561.	2.1	21
25	Decellularization technology in CNS tissue repair. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 493-500.	1.4	19
26	The role of lncRNAs in hepatocellular carcinoma: opportunities as novel targets for pharmacological intervention. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 331-340.	1.4	18
27	Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients. <i>Journal of Translational Medicine</i> , 2019, 17, 203.	1.8	18
28	Network Meta-Analysis of Randomized Controlled Trials. <i>Medicine (United States)</i> , 2015, 94, e609.	0.4	17
29	Kidney bioengineering in regenerative medicine: An emerging therapy for kidney disease. <i>Cytotherapy</i> , 2016, 18, 186-197.	0.3	17
30	Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 503-513.	2.0	17
31	Exosomal miR-3682-3p Suppresses Angiogenesis by Targeting ANGPT1 via the RAS-MEK1/2-ERK1/2 Pathway in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 633358.	1.8	17
32	Stratified neutrophil-to-lymphocyte ratio accurately predict mortality risk in hepatocellular carcinoma patients following curative liver resection. <i>Oncotarget</i> , 2016, 7, 5429-5439.	0.8	17
33	Efficacy of prophylactic probiotics in combination with antibiotics versus antibiotics alone for colorectal surgery: A meta-analysis of randomized controlled trials. <i>Journal of Surgical Oncology</i> , 2018, 117, 1394-1404.	0.8	16
34	Establishment and Validation of SSCLIP Scoring System to Estimate Survival in Hepatocellular Carcinoma Patients Who Received Curative Liver Resection. <i>PLoS ONE</i> , 2015, 10, e0129000.	1.1	15
35	Comparative efficacy of oral nucleotide analogues for the prophylaxis of hepatitis B virus recurrence after liver transplantation: a network meta-analysis. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 979-987.	2.0	15
36	Targeting HNRNPM Inhibits Cancer Stemness and Enhances Antitumor Immunity in Wnt-activated Hepatocellular Carcinoma. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 1413-1447.	2.3	15

#	ARTICLE	IF	CITATIONS
37	Comparative efficacy and safety between ablative therapies or surgery for small hepatocellular carcinoma: a network meta-analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 935-945.	1.4	13
38	Comparative efficacy and safety of immunosuppressive therapies for systemic sclerosis related interstitial lung disease: A Bayesian network analysis. <i>Modern Rheumatology</i> , 2020, 30, 687-695.	0.9	13
39	Aspartate aminotransferase-to-platelet ratio index predicts prognosis of hepatocellular carcinoma after postoperative adjuvant transarterial chemoembolization. <i>Cancer Management and Research</i> , 2019, Volume 11, 63-79.	0.9	12
40	Long-Term Survival Differences Between T1-2 Invasive Lobular Breast Cancer and Corresponding Ductal Carcinoma After Breast-Conserving Surgery: A Propensity-Scored Matched Longitudinal Cohort Study. <i>Clinical Breast Cancer</i> , 2019, 19, e101-e115.	1.1	12
41	MACROD2 deficiency promotes hepatocellular carcinoma growth and metastasis by activating GSK-3 β / β -catenin signaling. <i>Npj Genomic Medicine</i> , 2020, 5, 15.	1.7	12
42	Conditional survival estimate of acute-on-chronic hepatitis B liver failure: A dynamic prediction based on a multicenter cohort. <i>Oncotarget</i> , 2015, 6, 23261-23271.	0.8	12
43	Establishment and Validation of GV-SAPS II Scoring System for Non-Diabetic Critically Ill Patients. <i>PLoS ONE</i> , 2016, 11, e0166085.	1.1	11
44	Genetic Alterations and Transcriptional Expression of m6A RNA Methylation Regulators Drive a Malignant Phenotype and Have Clinical Prognostic Impact in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 900.	1.3	11
45	Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis. <i>Oncotarget</i> , 2015, 6, 24533-24549.	0.8	10
46	Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer. <i>BMC Cancer</i> , 2022, 22, 316.	1.1	10
47	Crosstalk Between Metabolism and Immune Activity Reveals Four Subtypes With Therapeutic Implications in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 861328.	2.2	10
48	Systematic Review With Network Meta-Analysis. <i>Medicine (United States)</i> , 2015, 94, e379.	0.4	9
49	Identification and validation of a new gene signature predicting prognosis of hepatocellular carcinoma patients by network analysis of stemness indices. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 699-709.	1.4	9
50	A multidimensional nomogram combining imaging features and clinical factors to predict the invasiveness and metastasis of combined hepatocellular cholangiocarcinoma. <i>Annals of Translational Medicine</i> , 2021, 9, 1518-1518.	0.7	9
51	New advances in liver decellularization and recellularization: innovative and critical technologies. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1183-1191.	1.4	8
52	Autophagy in ethanol-exposed liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1031-1037.	1.4	8
53	Survival-Associated Alternative Messenger RNA Splicing Signatures in Pancreatic Ductal Adenocarcinoma: A Study Based on RNA-Sequencing Data. <i>DNA and Cell Biology</i> , 2019, 38, 1207-1222.	0.9	7
54	<p><p>Comparative Effectiveness of Radiofrequency Ablation, Surgical Resection and Transplantation for Early Hepatocellular Carcinoma by Cancer Risk Groups: Results of Propensity Score-Weighted Analysis</p></p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 10389-10400.	1.0	7

#	ARTICLE	IF	CITATIONS
55	Parabolic relationship between sex-specific serum high sensitive C reactive protein and non-alcoholic fatty liver disease in chinese adults: a large population-based study. <i>Oncotarget</i> , 2016, 7, 14241-14250.	0.8	6
56	Risk stratification of LI-RADS M and LI-RADS 4/5 combined hepatocellular cholangiocarcinoma: prognostic values of MR imaging features and clinicopathological factors. <i>European Radiology</i> , 2022, 32, 5166-5178.	2.3	6
57	Recent advances in re-engineered liver: de-cellularization and Are-cellularization techniques. <i>Cytotherapy</i> , 2015, 17, 1015-1024.	0.3	5
58	Profiles of alternative splicing landscape in breast cancer and their clinical significance: an integrative analysis based on large-sequencing data. <i>Annals of Translational Medicine</i> , 2021, 9, 58-58.	0.7	3
59	Combined AFP-CRUT with microvascular invasion accurately predicts mortality risk in patients with hepatocellular carcinoma following curative liver resection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1127-1138.	1.4	2
60	Identification and Validation of a Tumour Microenvironment-Based Immune Molecular Subgroups for Gastric Cancer: Immunotherapeutic Implications. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
61	Genetic Alterations and Transcriptional Expression of m <sup>6</sup></sup>A RNA Methylation Regulators Drive a Malignant Phenotype and Have Clinical Prognostic Impact in Hepatocellular Carcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0